previous
report
colig
leukocyt
immunoglobulinlik
antibodyopson
denv
led
recruit
domaincontain
dephosphoryl
spleen
tyrosin
kinas
syk
reduc
interferon
stimul
gene
induct
show
also
signal
attenu
otherwis
rapid
acidif
lysosom
enzym
activ
follow
uptak
denv
reduc
slower
traffick
antibodyopson
denv
lytic
phagolysosom
compart
demonstr
colig
also
permit
denv
overcom
cellautonom
immun
respons
enhanc
intracellular
surviv
denv
find
provid
insight
antivir
drug
modifi
phagosom
acidif
use
virus
denv
last
decad
alon
global
burden
dengu
doubl
estim
million
symptomat
case
annual
risk
sever
diseas
augment
dengu
viru
denv
opson
nonor
subneutr
level
antibodi
ligat
fcgamma
receptor
rs
enhanc
entri
replic
monocyt
macrophag
dendrit
cell
phenomenon
term
antibodydepend
enhanc
ade
engend
elev
viraemia
vascular
leakag
characterist
sever
dengu
inde
recent
demonstr
ade
clinic
identifi
process
could
exploit
enhanc
live
attenu
viral
vaccin
ade
modifi
denv
entri
target
cell
r
howev
activ
variou
receptormedi
pathway
downregul
intracellular
innat
adapt
antivir
mechan
could
also
contribut
enhanc
dengu
pathogenesi
activ
rs
known
signal
phosphoryl
immunoreceptor
tyrosinebas
activ
motif
itam
spleen
tyrosin
kinas
syk
activ
syk
control
number
pathway
includ
actin
remodel
necessari
phagocytosi
interferonstimul
gene
isg
induct
independ
interferon
receptor
signal
induct
isg
would
creat
intracellular
environ
unfavor
enhanc
denv
replic
counter
earli
activ
rtrigger
antivir
respons
denv
colig
inhibitori
leukocyt
immunoglobulinlik
receptor
ade
recruit
domaincontain
dephosphoryl
syk
downregul
induct
isg
respons
besid
inhibit
earli
isg
induct
also
possibl
denv
alter
cellular
compartment
cellautonom
immun
respons
enhanc
replic
colig
especi
sinc
itamsyk
signal
axi
also
govern
rmediat
phagocytosi
previou
studi
focus
cellular
uptak
denv
perform
epitheli
cell
line
vero
collect
show
denv
enter
host
cell
via
clathrinmedi
endocytosi
denv
traffick
earli
late
endosom
undergo
fusion
acid
late
endosom
howev
denv
uptak
traffick
rout
may
vari
accord
type
host
cell
type
receptor
use
entri
moreov
understand
denv
traffick
follow
rmediat
uptak
implic
r
signal
itam
syk
could
modul
traffick
enhanc
viral
replic
ade
remain
nascent
show
signal
direct
denvcontain
phagosom
less
acidifi
compart
prevent
rapid
lysosom
degrad
denv
likewis
inhibit
phagosom
acidif
lysosomotrop
drug
also
led
increas
antibodydepend
infect
suggest
caution
use
drug
antidengu
therapi
isol
character
denv
endocyt
vesicl
previous
obtain
two
subclon
limit
dilut
cell
name
aderesist
adesuscept
subclon
support
similar
level
denv
uptak
infect
denv
condit
infect
ade
condit
led
significantli
higher
titr
compar
differ
suscept
ade
due
higher
level
express
antibodyopson
denv
colig
downregul
activ
rmediat
signal
reduc
induct
isg
enhanc
denv
replic
sinc
signal
modul
syk
activ
turn
regul
phagosom
traffick
matur
examin
reduc
syk
activ
result
alter
phagosom
compartment
denv
could
also
contribut
enhanc
viral
replic
ade
investig
compartment
modifi
adapt
protocol
previous
use
purif
latex
beadcontain
phagosom
step
sucros
gradient
isol
denv
endocyt
vesicl
follow
infect
subclon
denv
ade
condit
supplementari
fig
recoveri
denv
rna
abund
fraction
densest
fraction
collect
fig
similar
find
obtain
denv
endocyt
vesicl
isol
use
continu
sucros
gradient
allow
flotat
denvcontain
vesicl
buoyant
densiti
importantli
peak
viral
rna
recoveri
use
method
isol
correspond
fraction
similar
densiti
reinforc
reproduc
assay
fig
yield
viral
rna
recoveri
purif
denv
endocyt
vesicl
step
sucros
gradient
higher
method
use
subsequ
experi
particl
isol
fraction
step
sucros
gradient
character
use
nanosight
enabl
quantif
size
nanoparticl
size
endosom
lysosom
compart
rang
nm
nm
use
nanosight
allow
track
denv
cellular
endocyt
machineri
denv
first
label
tetramethylindodicarbocyanin
salt
lipophil
fluoresc
dye
follow
uptak
fusion
viru
host
cell
membran
fluoresc
unquench
allow
discrimin
didparticl
use
nanosight
fluoresc
mode
modal
size
didparticl
fold
larger
modal
size
nanoparticl
detect
light
scatter
mode
fig
supplementari
fig
importantli
major
didparticl
detect
fraction
denv
ade
infect
fig
consist
bulk
viral
rna
recov
fraction
fig
modal
size
nm
nm
didparticl
isol
follow
denv
ade
infect
respect
also
suggest
possibl
denv
contain
within
endosom
vesicl
fig
denv
traffick
lysosom
compart
upon
entri
western
blot
probe
express
endosom
traffick
marker
isol
fraction
reveal
lower
express
marker
earli
endosom
compart
rel
marker
late
endosom
compart
supplementari
fig
suggest
hour
postinfect
denv
compartment
late
endosom
lysosom
follow
uptak
host
cell
enrich
endosom
marker
isol
fraction
rel
whole
cell
lysat
valid
purif
denv
endocyt
vesicl
perform
step
sucros
gradient
supplementari
fig
organel
marker
also
use
verifi
puriti
denv
endocyt
vesicl
isol
although
golgi
apparatu
peroxisom
detect
er
calnexin
bip
mitochondria
coisol
denv
endocyt
vesicl
supplementari
fig
er
protein
known
mediat
phagosom
traffick
coisol
latex
bead
phagosom
could
import
denv
replic
sirna
knockdown
monocyt
cell
led
reduc
viral
replic
increas
product
also
detect
western
blot
attain
granular
level
inform
denv
compartment
alter
ade
perform
isobar
tag
rel
absolut
quantit
itraq
analysi
denv
endocyt
vesicl
isol
fraction
interestingli
lysosom
protein
enrich
reduc
ade
fig
convers
protein
involv
endocytosi
rmediat
phagocytosi
enrich
ade
fig
denv
traffick
lysosom
compart
ade
substanti
activ
lysosom
hydrolas
process
catalyt
activ
form
upon
phagosom
acidif
specif
express
activ
cathepsin
catd
lysosom
proteas
optim
activ
acid
ph
higher
compar
fig
lysosom
hydrolas
suggest
higher
level
phagosom
acidif
ade
test
syk
activ
affect
denv
phagosom
acidif
hallmark
phagosom
matur
label
denv
phsensit
phrodo
dye
phinsensit
alexa
fluor
dye
track
intracellular
denv
sinc
acidif
subcellular
environ
increas
fluoresc
intens
phrodo
ratio
fluoresc
intens
phrodo
serv
semiquantit
measur
phagosom
acidif
approach
previous
use
assess
phagosom
acidif
infect
bacteria
simultan
label
phrodo
phinsensit
fluoresc
probe
batch
denv
show
least
colabel
phrodo
supplementari
fig
use
subsequ
experi
test
denv
would
sensit
chang
phagosom
acidif
infect
vero
cell
pretreat
differ
concentr
chloroquin
cq
ph
intracellular
compart
increas
concentr
cq
use
fluoresc
intens
phrodo
decreas
observ
reduc
overlap
phrodo
e
protein
supplementari
fig
indic
denv
sensit
chang
ph
use
examin
semiquantit
differ
phagosom
acidif
use
denv
infect
subclon
ade
condit
show
higher
level
phagosom
acidif
ade
rel
fig
b
contrast
differ
phagosom
acidif
observ
denv
infect
subclon
fig
b
reduct
express
pretransfect
sirna
result
increas
phagosom
acidif
compar
pretransfect
scrambl
control
sirna
fig
convers
overexpress
led
expect
increas
level
reduc
phagosom
acidif
ade
fig
similar
find
recapitul
primari
monocyt
increas
phagosom
acidif
follow
ade
infect
observ
follow
pretreat
primari
monocyt
sodium
stiboglucon
inhibitor
fig
b
likewis
block
antibodi
primari
monocyt
increas
phagosom
acidif
ade
infect
fig
collect
data
indic
signal
reduc
acidif
denv
phagosom
like
prevent
denv
degrad
lysosom
enzym
viru
complet
uncoat
depend
low
ph
catalyst
e
protein
trimer
thought
conform
necessari
membran
fusion
releas
genom
cytosol
replic
howev
rmediat
uptak
antibodyopson
denv
ade
also
lead
rapid
denv
phagosom
acidif
number
western
blot
indic
level
rel
gapdh
dot
repres
singl
viru
particl
data
express
mean
sd
two
independ
experi
p
p
c
rfi
phrodo
normal
ade
infect
primari
monocyt
pretreat
isotyp
antibodi
control
c
coloc
phrodo
red
green
label
e
protein
cyan
hpi
primari
monocyt
pretreat
isotyp
antibodi
control
polyclon
antibodi
infect
ade
condit
scale
bar
dot
repres
singl
viru
particl
data
express
mean
sd
two
independ
experi
p
activ
lysosom
enzym
result
denv
degrad
reduc
slow
phagosom
acidif
ade
could
allow
denv
escap
lysosom
degrad
thu
promot
enhanc
intracellular
surviv
denv
albeit
delay
viral
uncoat
fusion
clarifi
phagosom
acidif
critic
determin
viral
releas
subsequ
viral
replic
test
inhibit
phagosom
acidif
lysosomotrop
weak
base
ammonium
chlorid
nh
cl
cq
could
result
enhanc
infect
ade
first
verifi
could
reproduc
inhibit
viral
replic
fig
infecti
denv
titr
fig
follow
denv
infect
cell
pretreat
nh
cl
signific
increas
cellular
cytotox
supplementari
fig
contrast
pretreat
subclon
either
nh
cl
cq
led
increas
viral
replic
infect
ade
condit
larger
magnitud
observ
fig
supplementari
fig
contrast
viral
replic
subclon
infect
denv
condit
significantli
reduc
either
cq
nh
cl
pretreat
supplementari
fig
pretreat
primari
monocyt
either
cq
nh
cl
infect
also
led
increas
viral
replic
larger
fold
increas
ade
compar
denv
condit
fig
f
supplementari
fig
increas
viral
replic
follow
cq
nh
cl
pretreat
consequ
result
increas
product
new
viral
progeni
cultur
supernat
ade
supplementari
fig
although
virion
reduc
infect
fig
h
due
expect
reduct
viral
matur
supplementari
fig
reduc
acidificationdepend
furin
activ
immatur
virus
could
nonetheless
patholog
import
abund
presenc
nonneutr
antiprm
antibodi
patient
secondari
denv
infect
could
render
immatur
virion
infecti
ade
profession
nonprofession
phagocyt
cellular
compartment
util
mean
selfdef
human
pathogen
compart
border
restrict
pathogen
access
cytosol
express
pattern
recognit
receptor
danger
receptor
aid
pathogen
detect
elimin
determin
denv
compartment
depend
mode
entri
thu
hitherto
unexplor
investig
could
provid
uniqu
insight
pathogenesi
dengu
plasma
membran
receptor
signal
viru
uptak
modul
denv
compartment
outcom
infect
denv
destin
phagolysosom
degrad
follow
rmediat
uptak
ade
consist
previou
find
phagosom
contain
antibodyopson
bead
matur
faster
phagolysosom
compar
uncoat
bead
furthermor
mycobacterium
tuberculosi
mtb
helicobact
pylori
opson
igg
result
rapid
phagosom
matur
effici
destroy
nonopson
bacteri
particl
find
studi
add
bodi
knowledg
ade
antibodyopson
denv
colig
itimbear
signal
dephosphoryl
syk
reduc
syk
signal
result
suppress
isg
induct
also
downregul
phagosom
acidif
permit
denv
escap
lysosom
degrad
thought
inhibit
phagosom
acidif
act
membran
fusion
phagosom
traffick
defect
phagosom
acidif
also
observ
defici
mous
macrophag
find
thu
agre
recent
studi
demonstr
increas
viral
fusion
ade
lead
enhanc
product
infecti
denv
titr
besid
denv
human
pathogen
also
known
subvert
phagosom
acidif
replic
surviv
exampl
mtb
express
bacteri
protein
tyrosin
phosphatas
ptpa
dephosphoryl
vacuolar
protein
sort
inhibit
recruit
vacuolartyp
h
atpas
vatpas
proton
pump
phagosom
inhibit
phagosom
acidif
mtb
infect
likewis
leishmania
donovani
express
glycolipid
lipophosphoglycan
insert
phagosom
membran
inhibit
recruit
cathepsin
vatpas
critic
phagosom
acidif
without
express
protein
specif
modifi
phagosom
acidif
denv
indirectli
alter
phagosom
environ
colig
antibodydepend
infect
rapid
phagosom
acidif
lysosom
protein
activ
key
earli
defens
mechan
infect
organ
phagosom
cargo
therapeut
approach
reli
rais
intracellular
ph
consid
cautious
detect
increas
magnitud
viral
replic
subclon
primari
monocyt
pretreat
cq
nh
cl
infect
denv
ade
condit
consist
find
infect
human
immunodefici
viru
type
sever
acut
respiratori
syndrom
coronaviru
also
rais
follow
pretreat
lysosomotrop
drug
host
cell
viru
abl
escap
lysosom
degrad
enter
host
cell
via
separ
endocyt
pathway
find
also
potenti
explain
least
part
cq
fail
show
therapeut
efficaci
proofofconcept
clinic
trial
dengu
patient
although
cq
nh
cl
treatmentrel
increas
viral
rna
replic
abundantli
secret
immatur
denv
could
nonetheless
detriment
patient
experienc
secondari
dengu
infect
form
major
trial
subject
prior
denv
infect
patient
would
like
produc
abund
crossreact
antiprm
antibodi
would
bind
immatur
denv
particl
enabl
entri
rbear
cell
subsequ
furin
activ
render
infecti
collect
find
suggest
denv
adopt
festina
lent
model
escap
phagolysosom
degrad
ensur
intracellular
surviv
ade
although
reduc
slow
phagosom
acidif
ade
may
delay
viral
fusion
uncoat
probabl
necessari
tradeoff
ultim
permit
denv
escap
lysosom
degrad
favor
intracellular
surviv
cell
virus
subclon
limit
dilut
primari
monocyt
isol
princip
investig
cultur
describ
previous
st
clinic
isol
singapor
gener
hospit
method
label
denv
previous
describ
dual
label
denv
phrodo
alexa
fluor
detail
supplementari
method
endotoxinfre
lal
chromogen
endotoxin
quantit
kit
pierc
chimer
humanmous
antibodi
construct
previous
describ
denv
incub
media
human
antibodi
gml
ad
cell
moi
indic
time
point
plaqu
assay
hr
hr
postinfect
protein
protein
phosphoryl
level
assess
use
western
blot
analyz
imagej
isol
denv
endocyt
vesicl
isol
denv
endocyt
vesicl
perform
use
protocol
previous
use
isol
latex
bead
phagosom
briefli
denv
incub
media
gml
hr
ad
moi
cell
incub
denv
immun
complex
min
transfer
cell
wash
pb
homogen
ice
stroke
use
syring
denv
endocyt
vesicl
isol
either
step
continu
sucros
gradient
l
fraction
continu
sucros
gradient
collect
subject
viral
rna
extract
use
qiaamp
viral
rna
mini
kit
qiagen
fraction
interfac
step
sucros
gradient
collect
l
subject
viral
rna
extract
denv
endocyt
vesicl
resuspend
ml
cold
pb
contain
proteas
inhibitor
wash
ultracentrifug
protein
pellet
resuspend
l
lysi
buffer
nonidet
mm
nacl
mm
tri
ph
presenc
proteas
phosphatas
inhibitor
sigma
protein
concentr
denv
endocyt
vesicl
determin
use
pierc
bca
protein
assay
kit
pierc
endocyt
vesicl
protein
g
separ
sdspage
gel
immunoblot
nanosight
custom
nm
bandpass
filter
use
fluoresc
mode
wash
denv
endocyt
vesicl
resuspend
appropri
dilut
hne
buffer
inject
lm
unit
ml
syring
nta
analyt
softwar
use
captur
analyz
data
sampl
video
durat
record
delay
record
chamber
temperatur
record
end
video
assess
phagosom
acidif
denv
denv
incub
media
gml
ad
cell
moi
cell
synchron
ice
min
follow
hr
infect
fix
pfa
confoc
immunofluoresc
use
assess
local
antibodyviru
complex
fluoresc
intens
phrodo
denv
cell
detail
descript
provid
supplementari
method
experi
conduct
least
biolog
replic
repeat
least
twice
mannwhitney
test
use
compar
differ
phagosom
acidif
experi
compar
two
mean
twotail
unpair
student
test
perform
use
graphpad
prism
p
